---
annotations:
- type: Pathway Ontology
  value: phase I biotransformation pathway
- type: Pathway Ontology
  value: cellular detoxification pathway
- type: Pathway Ontology
  value: phase II biotransformation pathway
- type: Pathway Ontology
  value: phase I biotransformation pathway via cytochrome P450
authors:
- Pieter Giesbertz
- Khanspers
- MaintBot
- MartijnVanIersel
- Ddigles
- DeSl
- Fehrhart
- AlexanderPico
- Egonw
description: Biotransformation is the chemical modification (or modifications) made
  by an organism on a chemical compound. If this modification ends in mineral compounds
  like CO2, NH4+, or H2O, the biotransformation is called mineralisation.  Biotransformation
  means chemical alteration of chemicals such as nutrients, amino acids, toxins, and
  drugs in the body. It is also needed to render non-polar compounds polar so that
  they are not reabsorbed in renal tubules and are excreted. Biotransformation of
  xenobiotics can dominate toxicokinetics and the metabolites may reach higher concentrations
  in organisms than their parent compounds. [https://en.wikipedia.org/wiki/Biotransformation]  Proteins
  on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP702
  CPTAC Assay Portal]
last-edited: 2019-09-12
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP702
- /instance/WP702
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP702.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: Biotransformation is the chemical modification (or modifications) made
    by an organism on a chemical compound. If this modification ends in mineral compounds
    like CO2, NH4+, or H2O, the biotransformation is called mineralisation.  Biotransformation
    means chemical alteration of chemicals such as nutrients, amino acids, toxins,
    and drugs in the body. It is also needed to render non-polar compounds polar so
    that they are not reabsorbed in renal tubules and are excreted. Biotransformation
    of xenobiotics can dominate toxicokinetics and the metabolites may reach higher
    concentrations in organisms than their parent compounds. [https://en.wikipedia.org/wiki/Biotransformation]  Proteins
    on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP702
    CPTAC Assay Portal]
  keywords:
  - CYP3A4
  - GSTT2B
  - MGST3
  - CYP27C1
  - CYP2C18
  - CYP2A7
  - CYP20A1
  - CYP2S1
  - NAT10
  - Substrate-Ac
  - CHST5
  - NAT14
  - AKR7A3
  - AKR1C1
  - FMO4
  - Substrate-SG
  - CHST6
  - NAT12
  - GSTT1
  - GSTA5
  - CYP4F2
  - CYP11B1
  - CHST11
  - CYP4F8
  - NAT8
  - GSTA1
  - SULT1A3
  - GSTCD
  - GSTA3
  - CYP4V2
  - UGT1A10
  - Methyltransferase
  - GSTO1
  - SULT1A2
  - CYP27A1
  - CYP3A7
  - AKR1D1
  - GSTP1
  - Substrate-Gl
  - GAL3ST1
  - CYP39A1
  - Substrate-Aa
  - CHST4
  - CYP51A1
  - GSTM3
  - GAL3ST2
  - GSR
  - UGT2A3
  - UGT2B11
  - EPHX1
  - CYP46A1
  - NAT8L
  - GPX3
  - AKR1C4
  - UGT1A1
  - CHST13
  - GSTM4
  - CYP3A5
  - GPX5
  - CYP2A13
  - CYP24A1
  - NDST2
  - Glutathione transferase
  - CYP26A1
  - CYP2U1
  - CYP7A1
  - CYP1A1
  - CYP4F3
  - HS2ST1
  - GPX4
  - HS3ST4
  - SULT1C3
  - Flavin monooxygenase
  - Amino acid acyltransferase
  - CYP27B1
  - TPMT
  - CYP26C1
  - SULT4A1
  - HS3ST6
  - SULT1C4
  - HS3ST5
  - FMO1
  - CYP8B1
  - CYP4X1
  - CYP11B2
  - KCNAB3
  - GSTA2
  - Substrate-NH2
  - SULT1A4
  - CYP450
  - HS6ST3
  - NAT6
  - FMO5
  - CHST2
  - UGT1A8
  - GSTM5
  - Substrate-SO3H
  - CYP4Z1
  - CYP26B1
  - MGST2
  - CHST3
  - CYP4F11
  - FMO2
  - MGST1
  - UGT2B7
  - COMT
  - CHST10
  - GLYATL1
  - SULT1B1
  - CYP2C8
  - CYP1A2
  - AKR1B1
  - NDST3
  - AKR1A1
  - CYP17A1
  - CYP21A2
  - CYP2E1
  - HS3ST3B1
  - GSTO2
  - NAT1
  - Substrate-SH
  - Sulfotransferase
  - CHST7
  - CYP2W1
  - GPX2
  - UGT2B28
  - GSTT2
  - UGT1A9
  - CYP3A43
  - Substrate-OH
  - AKR1C2
  - Substrate=O
  - NNMT
  - CYP11A1
  - CYP2D6
  - GSTM2
  - SULT2A1
  - CHST8
  - INMT
  - GLYAT
  - UGT1A4
  - NAT11
  - NAT2
  - AKR7A2
  - UGT1A3
  - HNMT
  - KCNAB1
  - NDST4
  - CYP2J2
  - UGT2B17
  - Substrate-O-R
  - UGT2A1
  - NDST1
  - GSTK1
  - GSTZ1
  - CYP7B1
  - CYP1B1
  - GSS
  - N-acetyltransferase
  - HS6ST2
  - CYP2C9
  - Aldo-keto reductase
  - UGT2B15
  - CYP19A1
  - CHST1
  - HS6ST1
  - GSTA4
  - HS3ST3A1
  - CHST12
  - CHST14
  - SULT1C1
  - SULT1C2
  - HS3ST1
  - GLYATL2
  - UGT1A5
  - CYP2B6
  - SULT6B1
  - Xenobiotic substrate
  - GPX1
  - AKR1B10
  - FMO3
  - CYP4F12
  - SULT1E1
  - UGT2A2
  - UGT1A7
  - Substrate-CH3
  - NAT9
  - UGT1A6
  - NAT13
  - CYP4F22
  - Glucuronosyltransferase
  - KCNAB2
  - SULT2B1
  - CYP2A6
  - HS3ST2
  - CYP2F1
  - CYP4B1
  - CYP2R1
  - CHST9
  - GAL3ST4
  - UGT2B4
  - GSTM1
  - GAL3ST3
  - BAAT
  - EPHX2
  - NAT5
  - CYP2C19
  - SULT1A1
  - AKR1C3
  license: CC0
  name: Metapathway biotransformation Phase I and II
seo: CreativeWork
title: Metapathway biotransformation Phase I and II
wpid: WP702
---